DK0637956T3 - Anvendelse af remacemid til behandling af Parkinsons sygdom - Google Patents
Anvendelse af remacemid til behandling af Parkinsons sygdomInfo
- Publication number
- DK0637956T3 DK0637956T3 DK93911903T DK93911903T DK0637956T3 DK 0637956 T3 DK0637956 T3 DK 0637956T3 DK 93911903 T DK93911903 T DK 93911903T DK 93911903 T DK93911903 T DK 93911903T DK 0637956 T3 DK0637956 T3 DK 0637956T3
- Authority
- DK
- Denmark
- Prior art keywords
- remacemide
- parkinson
- disease
- treatment
- conjuction
- Prior art date
Links
- YSGASDXSLKIKOD-UHFFFAOYSA-N 2-amino-N-(1,2-diphenylpropan-2-yl)acetamide Chemical compound C=1C=CC=CC=1C(C)(NC(=O)CN)CC1=CC=CC=C1 YSGASDXSLKIKOD-UHFFFAOYSA-N 0.000 title abstract 3
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 229950000659 remacemide Drugs 0.000 title abstract 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929209599A GB9209599D0 (en) | 1992-05-02 | 1992-05-02 | Novel therapy for the treatment of parkinsons disease |
PCT/GB1993/000908 WO1993021910A1 (en) | 1992-05-02 | 1993-04-30 | Use of remacemide for the treatment of parkinson's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0637956T3 true DK0637956T3 (da) | 1999-11-22 |
Family
ID=10714969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK93911903T DK0637956T3 (da) | 1992-05-02 | 1993-04-30 | Anvendelse af remacemid til behandling af Parkinsons sygdom |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0637956B1 (da) |
JP (1) | JP3542801B2 (da) |
KR (1) | KR950701216A (da) |
AT (1) | ATE181669T1 (da) |
CA (1) | CA2134783C (da) |
DE (1) | DE69325512T2 (da) |
DK (1) | DK0637956T3 (da) |
ES (1) | ES2135476T3 (da) |
GB (1) | GB9209599D0 (da) |
GR (1) | GR3031320T3 (da) |
HU (1) | HU211305A9 (da) |
IL (1) | IL105569A (da) |
NZ (2) | NZ299042A (da) |
SG (1) | SG49202A1 (da) |
WO (1) | WO1993021910A1 (da) |
ZA (1) | ZA933086B (da) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6025369A (en) * | 1996-05-03 | 2000-02-15 | The Board Of Regents Of The University Nebraska | N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis |
WO2003079972A2 (en) | 2002-02-22 | 2003-10-02 | New River Parmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
AU2007346591A1 (en) | 2007-02-07 | 2008-08-14 | Gosforth Centre (Holdings) Pty Ltd | Treatment of ADHD |
JP2011529923A (ja) | 2008-08-06 | 2011-12-15 | ゴスフォース センター(ホールディングス)プロプライエタリー リミテッド | 精神障害(psychiatricdisorder)を治療するための組成物および方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU639722B2 (en) * | 1989-10-27 | 1993-08-05 | Astra Aktiebolag | Use of arylalkylamides in the treatment of neurodegenerative diseases |
DE3940410A1 (de) * | 1989-12-04 | 1991-06-06 | Schering Ag | Neue verwendung von nmda-rezeptor-antagonisten |
-
1992
- 1992-05-02 GB GB929209599A patent/GB9209599D0/en active Pending
-
1993
- 1993-04-30 DK DK93911903T patent/DK0637956T3/da active
- 1993-04-30 JP JP51908793A patent/JP3542801B2/ja not_active Expired - Fee Related
- 1993-04-30 WO PCT/GB1993/000908 patent/WO1993021910A1/en active IP Right Grant
- 1993-04-30 EP EP93911903A patent/EP0637956B1/en not_active Expired - Lifetime
- 1993-04-30 NZ NZ299042A patent/NZ299042A/en not_active IP Right Cessation
- 1993-04-30 NZ NZ252728A patent/NZ252728A/en not_active IP Right Cessation
- 1993-04-30 KR KR1019940703908A patent/KR950701216A/ko not_active Application Discontinuation
- 1993-04-30 ZA ZA933086A patent/ZA933086B/xx unknown
- 1993-04-30 AT AT93911903T patent/ATE181669T1/de not_active IP Right Cessation
- 1993-04-30 CA CA002134783A patent/CA2134783C/en not_active Expired - Fee Related
- 1993-04-30 SG SG1996007583A patent/SG49202A1/en unknown
- 1993-04-30 DE DE69325512T patent/DE69325512T2/de not_active Expired - Fee Related
- 1993-04-30 ES ES93911903T patent/ES2135476T3/es not_active Expired - Lifetime
- 1993-04-30 IL IL105569A patent/IL105569A/xx not_active IP Right Cessation
-
1995
- 1995-06-23 HU HU95P/P00425P patent/HU211305A9/hu unknown
-
1999
- 1999-09-23 GR GR990402420T patent/GR3031320T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
SG49202A1 (en) | 1998-05-18 |
KR950701216A (ko) | 1995-03-23 |
IL105569A (en) | 1997-11-20 |
NZ252728A (en) | 1996-11-26 |
JPH07506105A (ja) | 1995-07-06 |
IL105569A0 (en) | 1993-08-18 |
WO1993021910A1 (en) | 1993-11-11 |
EP0637956A1 (en) | 1995-02-15 |
DE69325512T2 (de) | 1999-12-16 |
CA2134783C (en) | 2002-08-13 |
JP3542801B2 (ja) | 2004-07-14 |
DE69325512D1 (de) | 1999-08-05 |
ATE181669T1 (de) | 1999-07-15 |
HU211305A9 (en) | 1995-11-28 |
CA2134783A1 (en) | 1993-11-11 |
GR3031320T3 (en) | 1999-12-31 |
NZ299042A (en) | 2000-07-28 |
ZA933086B (en) | 1993-11-01 |
ES2135476T3 (es) | 1999-11-01 |
EP0637956B1 (en) | 1999-06-30 |
GB9209599D0 (en) | 1992-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI20000720L (fi) | Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi | |
PT100199A (pt) | Combinacao antiviral de nucleosidos e processo para a sua preparacao | |
CY2009018I2 (el) | Φαρμακευτικη συνθεση περιλαμβανουσα πιογλιταζονη και γλιμεπιριδη για χρηση στην θεραπεια του διαβητη | |
ATE131730T1 (de) | Nukleosidanalogen enthaltende antiviren- zubereitungen | |
NO952309D0 (no) | Anvendelse av riluzol ved behandling av Parkinsons sykdom og Parkinsonske syndromer | |
RU96116802A (ru) | Перевязочный материал | |
ITRM910002A0 (it) | Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento. | |
FR2735475B1 (fr) | Derives de n-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl) benzamide, leur preparation et leur application en therapeutique | |
DK0637956T3 (da) | Anvendelse af remacemid til behandling af Parkinsons sygdom | |
NO302170B1 (no) | Enantiomerisk 1-fenyl-2-(2-pyridinyl)etylamin, farmasöytisk formulering og anvendelse derav | |
ITMI910658A0 (it) | N-(4,5-diidrossi-e 4,5,8-triidrossi-9,10-diidro-9,10-diosso-2- antracen-il)carbonil) amminoacidi utilizzabili nella terapia delle affezioni osteoarticolari | |
NO944809L (no) | Biologisk aktive ureidoderivater som er nyttig i behandling av lentivirus-indusert sykdom | |
SE8802323D0 (sv) | 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it | |
FR2818147B1 (fr) | Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine | |
ITMI940030A0 (it) | Compressa farmaceutica ad eleavata e rapida disponibilita' del principio attivo in essa veicolato | |
RU96118559A (ru) | Лекарственное средство | |
ITBO930460A0 (it) | Procedimento per preparare forme farmaceutiche a rilascio controllato del principio attivo e le forme farmaceutiche cosi' ottenute. | |
FR2700115B1 (fr) | Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens. | |
ITBO920455A1 (it) | Procedimento per preparare forme farmaceutiche a rilascio controllato ritardato del principio attivo e le forme farmaceutiche cosi' ottenute. | |
IT1275987B1 (it) | Composizione farmaceutica attiva nella cura di affezioni dermatologiche | |
IT9022457A0 (it) | Composizione farmaceutica ad attivita' antiemorroidale e sua utilizzazione nella preparazione di forme farmaceutiche appropriate | |
ITMI910083A1 (it) | Composizione farmaceutica ad attivita' antiemorroidale e sua utilizzazione nella preparazione di forme farmaceutiche appropriate | |
ITCA950008A0 (it) | Impiego di combinaqzioni di analoghi di nucleosidi nella terapia delleinfezioni dell'aids. | |
TH14332A (th) | อนุพันธ์ของอาร์จีนีน | |
ITDP920008A1 (it) | Ustion-guariflash/ prodotto terapeutico per ustioni e piaghe infette, abrasioni, irritazioni cutanee, escoriazioni, senza controinicazioni,per uso esterno. farmaco di nuovissima invenzione, inesistente in commercio, tanto in italia che all'estero. |